Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5894774 | 0.98 | MEN1 (0.50) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL9564649 | 0.98 | MEN1 (0.50) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL9564618 | 0.98 | MEN1 (0.50) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL9564624 | 0.98 | MEN1 (0.50) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL9564643 | 0.98 | MEN1 (0.50) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL9564658 | 0.98 | MEN1 (0.50) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL9564627 | 0.98 | MEN1 (0.50) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL9564650 | 0.98 | MEN1 (0.50) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL9564615 | 0.98 | MEN1 (0.50) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL9564619 | 0.98 | MEN1 (0.50) | MEN1KMT2AHTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0882730-B1 | PHOSPHONIC ACID DIESTER DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2002-10-02 | — | — | EP | disclosed |
| CN-1070863-C | Phosphonic diester derivatives | OTSUKA PHARMA CO LTD (JP) | 2001-09-12 | — | — | CN | disclosed |
| US-5985858-A | TREATING AND PREVENTING HYPERLIPIDEMIA, DIABETES AND CATARACT, OR AS AN ANTITUMOR AGENT | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1999-11-16 | — | — | US | disclosed |
| CN-1206419-A | Phosphonic acid diester derivatives | OTSUKA PHARMA CO LTD (JP) | 1999-01-27 | — | — | CN | disclosed |
| EP-0882730-A1 | PHOSPHONIC ACID DIESTER DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0569328-A1 | Bis-phosphite stabilized compositions | CIBA-GEIGY AG (CH) | 1993-11-10 | — | — | EP | disclosed |
| EP-0192167-A1 | Use of thio-substitued ketones as photoinitiators | MERCK PATENT GmbH (DE) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MEN1 3295/4885KMT2A 4267/4885HTT 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.